Over expression of B7-H1 (also named PDL-1 or CD 274) molecule in cancer has been
linked to worse prognosis and resistance to anti-cancer therapies in several malignancies …

Abstract B7-H3 (also known as CD276) is a newly found molecule of B7 family, which may
be a promising target for cancer treatment. B7-H3 protein was demonstrated to be …

Purpose: The immune checkpoint PD-1 and its receptor B7-H1 (PD-L1) are successful
therapeutic targets in cancer but less is known about other B7 family members. Here, we …

Abstract B7-H3 (CD276 molecule) is an immune checkpoint from the B7 family of molecules
that acts more as a co-inhibitory molecule to promote tumor progression. It is abnormally …

The field of immunotherapy is a continually expanding niche in cancer biology research. In
the last two decades, there has been significant progress in identifying better targets and …

Abstract B7-H3 (CD276) is an important immune checkpoint member of the B7 and CD28
families. Induced on antigen-presenting cells, B7-H3 plays an important role in the inhibition …

B7-H1 (B7 homologue 1, PD-L1), expressed on the surface of tumor cells or antigen-
presenting cells in the tumor microenvironment, can suppress antitumor immune reaction …

Immunotherapy for cancer is a rapidly developing treatment that modifies the immune
system and enhances the antitumor immune response. B7-H3 (CD276), a member of the B7 …

Immunotherapy aiming at suppressing tumor development by relying on modifying or
strengthening the immune system prevails among cancer treatments and points out a new …

Background Resistance to chemotherapy is a major obstacle in the effective treatment of
cancer patients. B7-homolog 1, also known as programmed death ligand-1 (PD-L1), is an …